A "First of Its Kind" Tech Stock Trading for Cheap 🚀

Biotech is leading today's premarket gainers. Get a full report on all 4 top stocks inside [Image](www.elitetrade.club) Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. It's Wednesday, October 26th. Let's get ready to trade! Markets 📈 The S&P 500 advanced 1.6% on Tuesday as US benchmarks rallied for the second time this week. The Dow added 1.0%, and the Nasdaq closed with a 2.2% gain. Even the small-cap Russell 2K got in on the action with a 2.7% rally. Today, futures are dipping ahead of the opening bell. S&P 500 contracts are currently showing a 0.6% loss. Sponsored [A "First of Its Kind" Tech Stock Trading for Cheap]( Are you on the prowl for a Nasdaq traded company that might be flying under-the radar? Good. You've come to the right place. We've uncovered a little-known tech firm that could disrupt multiple billion dollar markets in the near future. The stock is still flying under Wall Street's radar... But, who knows how long that will last. Best of all, this company just made an acquisition that could give it an edge on the competition in an underserved market. [Click Here to Get the Stock's Ticker and an In-Depth Analysis]( Premarket Highlights 🔎 - Big Tech Earnings Disappoint: Microsoft and Google posted disappointing earnings results after Tuesday's closing bell, sparking declines in US benchmarks. What to Watch Today 👀 Tech Slide Yesterday's Big Tech earnings results put investors into a sour mood coming into the session. The earnings reports revealed that even big firms like MSFT and GOOG aren't immune to the worsening economic conditions in the US. Nasdaq-100 futures are currently down 1.7%, indicating a tech selloff is likely in today's session. International 🌍 Asia Hong Kong's Hang Seng Composite gained 1.0% overnight, while Japan's Nikkei 225 added 0.6%. The Shanghai Composite advanced 0.7%. Europe European stocks are down and headed lower midway through their session. The UK's FTSE 100 is down 0.4%, and the Euro Stoxx 600 is down 0.2%. Major Earnings 💰 Thermo Fisher Scientific Inc [TMO] ... AM Bristol-Myers Squibb Company [BMY] ... AM Automatic Data Processing, Inc. [ADP] ... AM Boeing Company (The) [BA] ... AM Waste Management, Inc. [WM] ... AM General Dynamics Corporation [GD] ... AM Cme Group Inc. [CME] ... AM Boston Scientific Corporation [BSX]... AM Meta Platforms, Inc.[META] ... PM Servicenow, Inc. [NOW] ... PM Economy 🏗 - Trade in goods (advance) [Sep] ... 8:30a - New home sales (SAAR) [Sep] ... 10a Running Hot 🔥 Gainers - Ensyce Bioscience [ENSC] >> +46.4% - Myomo [MYO] >> +54.8% - Lilium [LILMW] >> +49.0% Decliners - Thermogenesis Holdings [THMO] >> (46.9%) - Sierra Metals [SMTS] >> (27.4%) - Revelation Bio [REVB] >> (18.2%) Enphase Energy Inc [ENPH] - Last Close: $265.59 An upbeat earnings report is giving Enphase Energy a premarket boost. The solar energy company reported better-than-expected earnings and revenues on its Q3 earnings release after Tuesday's closing bell. Enphase reported non-GAAP EPS of $1.25 in Q3, which beat The Street's $1.09 EPS target by a wide margin. Revenues of $634.7 million also easily topped the consensus estimate of $615.9 million. Enphase's Q4 revenues guidance of $680 million to $720 million surpassed analysts' expectation of $663.6 million. ENPH is leading the S&P 500 with a 5.5% gain in today's premarket. My Take: ENPH seems to be in an up-trend as investors are hoping that a green energy-friendly White House could be a boon for solar stocks, even in a recession. However, this stock is very overvalued with a 187.29 P/E, so share prices could drop like a stone if sentiment shifts. Transcode Therapeutics Inc [RNAZ] - Last Close: $1.08 Upbeat drug data is lifting shares of Transcode Therapeutics. The biopharma firm reported positive preclinical results from its lead pancreatic adenocarcinoma candidate TTX-MC138. Forty percent of animals treated with TTX-MC138 had complete responses, defined as complete regression of disease and long-term survival without recurrence. Additional studies to better define the optimal dose and therapeutic window in pancreatic cancer are ongoing. CEO Michael Dudley says the company plans to submit an exploratory Investigational New Drug Application (eIND) this year for first-in-human (FIH) trials with TTX-MC138 in cancer patients. RNAZ is up 31.4%, and it's one of this morning's highest-volume premarket movers. My Take: It's anyone's guess whether TTX-MC138 will make it through to approval. Either way, it'll take years to all shake out. A position in this tiny biotech is more or less a crap shoot. Finance of America Companies Inc [FOA] - Last Close: $1.53 Finance of America is trending in the wake of a big announcement. On Monday morning, the financial services company announced plans to discontinue its forward mortgage originations business across retail and wholesale channels by the end of the year. The move will allow the company to focus its efforts on growing businesses with greater growth potential, says interim CEO Graham Fleming. According to the press release, the company will also look to partner with large mortgage lenders and other financial service providers, so it can offer more specialty services on its platform. FOA is one of this morning's top premarket stocks with a 33.9% gain. My Take: Shares of FOA initially fell on this news, but the market seems to be changing its mind over the past couple of days. FOA gained 2.0% on Tuesday, and it's adding to the rebound rally today. This could be a momentum opportunity. Cosmos Therapeutics [COSM] - Last Close: $0.0873 Cosmos Therapeutics is on the rise on news of a huge insider buy. A regulatory filing revealed the integrated pharmacy company's CEO, Grigorios Siokas, invested roughly $1.5 million to buy 12.5 million shares of its common stock. At that rate, Siokas paid about $0.12 apiece to acquire the shares. Cosmos also recently announced plans for a $7.5 million upsized public offering at $0.12 per share. COSM is one of this morning's most active stocks, and it's currently showing a 15.3% gain. My Take: The CEO is buying shares for $0.12, and the company's upcoming offering is priced at $0.12. So, It seems like this stock is undervalued at $0.0873 per share. That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... If you're on the hunt for a new broker, check out our preferred partner, moomoo! You can [get 15 free stocks]( worth up to $2,000 each if you join the moomoo App now. [Click here to get started.]( P.P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 or [click here]( to sign up now and get our watchlists sent directly to your phone! Or text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](